Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: A single-center experience

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 3, 2014, Pages 388-394

  De Luca, Giuseppe ^a   Verdoia, Monica ^a   Schaffer, Alon ^a   Suryapranata, Harry ^b   Parodi, Guido ^c   Antoniucci, David ^c   Marino, Paolo ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

ACS; Clopidogrel; PCI; Prasugrel; Switch therapy

Indexed keywords

CLOPIDOGREL; PRASUGREL; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG SUBSTITUTION; MIDDLE AGED;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE;

EID: 84906937148     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1039-0     Document Type: Article

References (25)

1. De Luca G, Cassetti E, Marino P (2009) Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med 27:712-719
2. De Luca G, Biondi-Zoccai G, Marino P (2008) Transferring patients with ST-egmsent elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. Ann Emerg Med 52:665-676
3. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937-948 (Pubitemid 47393576)
4. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998-1008 (Pubitemid 46376800)
5. De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW, Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation (2012) Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 172:611-621
6. De Luca G, Navarese EP, Suryapranata H (2013) A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 166:606-612
7. De Luca G, Ernst N, van 't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H (2006) Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J 151:1256-1259 (Pubitemid 43866607)
8. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115:813-818 (Pubitemid 46294748)
9. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW; for the DESERT cooperation (2013). Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost; 110. doi:10.1160/TH13-02-0092
10. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 116:2923-2932 (Pubitemid 350291199)
11. Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213-223
12. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015 (Pubitemid 350106708)
13. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, TRITON-TIMI 38 investigators, (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723-731
14. De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P (2013) Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience. Int J Cardiol 167:561-563
15. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD (2004) Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148:764-775
16. The Thrombolysis in Myocardial Infarction (TIMI) trial (1985) Phase I findings. TIMI Study Group. N Engl J Med 312:932-936
17. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203-2216 (Pubitemid 44791162)
18. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van EsGA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344-2351 (Pubitemid 46685903)
19. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB, SWAP Investigators (2010) Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56:1017-1023
20. Payne CD, Li YG, Brandt JT, Jakubowski JA, Small DS, Farid NA, Salazar DE, Winters KJ (2008) Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 19:275-281 (Pubitemid 351874155)
21. Diodati JD, Fung A, Saucedo JF, Oguzhan A, Gaxiola E, Cardillo TE, Effron MB, Fisher HN, Henneges C, Angiolillo DJ (2012) Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients: the TRIPLET trial. Can J Cardiol 28:S377 (724 Abstract)
22. Loh JP, Pendyala LK, Kitabata H, Torguson R, Chen F, Kent KM, Satler LF, Suddath WO, Pichard AD, Waksman R (2013) Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 111:841-845
23. De Luca G, Schaffer A, Wirianta J, Suryapranata H (2013) Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI. Int J Cardiol. doi:10.1016/j.ijcard.2013.01.161
24. Parodi G, De Luca G, Moschi G, Bellandi B, Valenti R, Migliorini A, Carrabba N, Antoniucci D (2010) Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. J Thromb Thrombolysis 30:446-451
25. De Luca G, Parodi G, Antoniucci D (2010) Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis. J Thromb Thrombolysis 30:452-458